IMAB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 21, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for IMAB moved out of overbought territory on November 06, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on November 27, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on IMAB as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMAB broke above its upper Bollinger Band on October 31, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
IMAB moved above its 50-day moving average on November 01, 2023 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMAB crossed bullishly above the 50-day moving average on November 07, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 195 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.384) is normal, around the industry mean (20.463). P/E Ratio (38.314) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (15.649) is also within normal values, averaging (329.780).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with RLAY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then RLAY could also see price increases.